Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

John G. Page, Baohong Tian, Karen Schweikart, Joseph Tomaszewski, Ray Harris, Trevor Broadt, Judith Polley-Nelson, Patricia E. Noker, Minghui Wang, Sharmila K. Makhija, Rose Aurigemma, David T. Curiel, Ronald D. Alvarez

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: The purpose of this study was to evaluate the biodistribution and toxicity of the tropism-modified infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-arginine-glycine-aspartate (RGD). Study Design: Cohorts of cotton rats were treated intravenously or intraperitoneally for 3 consecutive days with 5 × 108 to 5 × 1011 particles/kg of Ad5-Δ24-RGD or controls and killed on day 8, 17, or 56. For biodistribution studies, tissue samples from 14 organ sites and serum samples were evaluated for the presence of virus with the use of quantitative polymerase chain reaction analysis. For toxicity experiments, tissue samples from more than 30 organ sites and serum samples were obtained for the assessment of vector-related tissue or laboratory effects. Results: Ad5-Δ24-RGD was noted in tested samples at days 8 and 17 in animals that were treated intravenously and intraperitoneally with clearance by day 56. There were lower copies of vector noted in the blood and liver specimens of intraperitoneally treated animals. Mild peritonitis histopathologic findings were noted in rats that were treated intraperitoneally with Ad5-Δ24-RGD; pathologic findings did not vary significantly with dose, over time, or in comparison to that noted in animals that were treated with Ad5-Δ24. Conclusion: These studies provide critical insights regarding Ad5-Δ24-RGD dosing and anticipated toxicity for a planned clinical trial for ovarian cancer.

Original languageEnglish (US)
JournalAmerican Journal of Obstetrics and Gynecology
Volume196
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Adenoviridae
Ovarian Neoplasms
Safety
Sigmodontinae
Tropism
Peritonitis
Serum
Glycine
Cohort Studies
Clinical Trials
Viruses
Polymerase Chain Reaction
Liver

Keywords

  • biodistribution study
  • toxicity
  • vector
  • virotherapy

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. / Page, John G.; Tian, Baohong; Schweikart, Karen; Tomaszewski, Joseph; Harris, Ray; Broadt, Trevor; Polley-Nelson, Judith; Noker, Patricia E.; Wang, Minghui; Makhija, Sharmila K.; Aurigemma, Rose; Curiel, David T.; Alvarez, Ronald D.

In: American Journal of Obstetrics and Gynecology, Vol. 196, No. 4, 04.2007.

Research output: Contribution to journalArticle

Page, John G. ; Tian, Baohong ; Schweikart, Karen ; Tomaszewski, Joseph ; Harris, Ray ; Broadt, Trevor ; Polley-Nelson, Judith ; Noker, Patricia E. ; Wang, Minghui ; Makhija, Sharmila K. ; Aurigemma, Rose ; Curiel, David T. ; Alvarez, Ronald D. / Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. In: American Journal of Obstetrics and Gynecology. 2007 ; Vol. 196, No. 4.
@article{de41a316fba34835b79fcfea65933a96,
title = "Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer",
abstract = "Objective: The purpose of this study was to evaluate the biodistribution and toxicity of the tropism-modified infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-arginine-glycine-aspartate (RGD). Study Design: Cohorts of cotton rats were treated intravenously or intraperitoneally for 3 consecutive days with 5 × 108 to 5 × 1011 particles/kg of Ad5-Δ24-RGD or controls and killed on day 8, 17, or 56. For biodistribution studies, tissue samples from 14 organ sites and serum samples were evaluated for the presence of virus with the use of quantitative polymerase chain reaction analysis. For toxicity experiments, tissue samples from more than 30 organ sites and serum samples were obtained for the assessment of vector-related tissue or laboratory effects. Results: Ad5-Δ24-RGD was noted in tested samples at days 8 and 17 in animals that were treated intravenously and intraperitoneally with clearance by day 56. There were lower copies of vector noted in the blood and liver specimens of intraperitoneally treated animals. Mild peritonitis histopathologic findings were noted in rats that were treated intraperitoneally with Ad5-Δ24-RGD; pathologic findings did not vary significantly with dose, over time, or in comparison to that noted in animals that were treated with Ad5-Δ24. Conclusion: These studies provide critical insights regarding Ad5-Δ24-RGD dosing and anticipated toxicity for a planned clinical trial for ovarian cancer.",
keywords = "biodistribution study, toxicity, vector, virotherapy",
author = "Page, {John G.} and Baohong Tian and Karen Schweikart and Joseph Tomaszewski and Ray Harris and Trevor Broadt and Judith Polley-Nelson and Noker, {Patricia E.} and Minghui Wang and Makhija, {Sharmila K.} and Rose Aurigemma and Curiel, {David T.} and Alvarez, {Ronald D.}",
year = "2007",
month = "4",
doi = "10.1016/j.ajog.2006.12.016",
language = "English (US)",
volume = "196",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

AU - Page, John G.

AU - Tian, Baohong

AU - Schweikart, Karen

AU - Tomaszewski, Joseph

AU - Harris, Ray

AU - Broadt, Trevor

AU - Polley-Nelson, Judith

AU - Noker, Patricia E.

AU - Wang, Minghui

AU - Makhija, Sharmila K.

AU - Aurigemma, Rose

AU - Curiel, David T.

AU - Alvarez, Ronald D.

PY - 2007/4

Y1 - 2007/4

N2 - Objective: The purpose of this study was to evaluate the biodistribution and toxicity of the tropism-modified infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-arginine-glycine-aspartate (RGD). Study Design: Cohorts of cotton rats were treated intravenously or intraperitoneally for 3 consecutive days with 5 × 108 to 5 × 1011 particles/kg of Ad5-Δ24-RGD or controls and killed on day 8, 17, or 56. For biodistribution studies, tissue samples from 14 organ sites and serum samples were evaluated for the presence of virus with the use of quantitative polymerase chain reaction analysis. For toxicity experiments, tissue samples from more than 30 organ sites and serum samples were obtained for the assessment of vector-related tissue or laboratory effects. Results: Ad5-Δ24-RGD was noted in tested samples at days 8 and 17 in animals that were treated intravenously and intraperitoneally with clearance by day 56. There were lower copies of vector noted in the blood and liver specimens of intraperitoneally treated animals. Mild peritonitis histopathologic findings were noted in rats that were treated intraperitoneally with Ad5-Δ24-RGD; pathologic findings did not vary significantly with dose, over time, or in comparison to that noted in animals that were treated with Ad5-Δ24. Conclusion: These studies provide critical insights regarding Ad5-Δ24-RGD dosing and anticipated toxicity for a planned clinical trial for ovarian cancer.

AB - Objective: The purpose of this study was to evaluate the biodistribution and toxicity of the tropism-modified infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-arginine-glycine-aspartate (RGD). Study Design: Cohorts of cotton rats were treated intravenously or intraperitoneally for 3 consecutive days with 5 × 108 to 5 × 1011 particles/kg of Ad5-Δ24-RGD or controls and killed on day 8, 17, or 56. For biodistribution studies, tissue samples from 14 organ sites and serum samples were evaluated for the presence of virus with the use of quantitative polymerase chain reaction analysis. For toxicity experiments, tissue samples from more than 30 organ sites and serum samples were obtained for the assessment of vector-related tissue or laboratory effects. Results: Ad5-Δ24-RGD was noted in tested samples at days 8 and 17 in animals that were treated intravenously and intraperitoneally with clearance by day 56. There were lower copies of vector noted in the blood and liver specimens of intraperitoneally treated animals. Mild peritonitis histopathologic findings were noted in rats that were treated intraperitoneally with Ad5-Δ24-RGD; pathologic findings did not vary significantly with dose, over time, or in comparison to that noted in animals that were treated with Ad5-Δ24. Conclusion: These studies provide critical insights regarding Ad5-Δ24-RGD dosing and anticipated toxicity for a planned clinical trial for ovarian cancer.

KW - biodistribution study

KW - toxicity

KW - vector

KW - virotherapy

UR - http://www.scopus.com/inward/record.url?scp=33947702021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947702021&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2006.12.016

DO - 10.1016/j.ajog.2006.12.016

M3 - Article

C2 - 17403430

AN - SCOPUS:33947702021

VL - 196

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -